Mayne’s Generics Segment Sees Double-Digit Drop In Sales

Mayne Pharma’s generics business reported sales of AUS$253.0m (US$169.8m) for its financial year ending 30 June 2020, a 21% drop compared with a year earlier in AUS$ terms, and 26% in US$ terms. The generics segment, which is focused on the US market, also saw a 42% drop in full-year gross profit to AUS$95.7m.

South Australia-based Mayne said that its generics business was impacted by competition on its key products including liothyronine, dofetilide and...